Citations

Clear

3314 citation(s) found for "Do, Alexander".

Influence of Macrotroponin on the 99th Percentile Threshold in 2 High-Sensitivity Cardiac Troponin Assays
Strandkjær, Nina , Hansen, Morten Bagge , Hasselbalch, Rasmus Bo , Knudsen, Sophie Sander , Kronborg, Alexander Holst , Kamstrup, Pia R. , Kobylecki, Camilla J. , Hilsted, Linda , Dahl, Morten , Overgaard, Martin , Banerjee, Aditi , Ladefoged, Søren , Bundgaard, Henning , Jaffe, Allan S. , Iversen, Kasper , Hammarsten, Ola , Afzal, Shoaib , Hasselbalch, Rasmus Bo , Kobylecki, Camilla Jannie , Bundgaard, Henning , Jaffe, Allan S. , Iversen, Kasper Karmark , Kamstrup, Pia Rørbæk , Dahl, Morten , Kristensen, Jonas Henrik , Banerjee, Aditi

Mayo Clinic

Clinical Chemistry | May 21, 2025 | Volume: 71 | Issue: 8 | Pages: 884-895

10.1093/clinchem/hvaf068 | PMID 40492538 Get It

Abstract Background Cardiac troponin (cTn) levels exceeding the 99th percentile upper reference limit and a rise/fall pattern are key for diagnosing myocardial injury and infarction. Macrotroponins, formed by patient anti-cTn antibodies targeting cTn, can cause persistently elevated cTn levels without ongoing myocardial injury. The frequency and impact of macrotroponin interference on cTn 99th percentiles are unclear. This study compares sex-specific 99th percentiles for 2 cTn assays, before and after excluding macrotroponin-positive samples, focusing on the top 10% of cTn levels. Methods We examined 1058 plasma samples from healthy individuals previously used for Danish cTn 99th percentiles. Following International Federation of Clinical Chemistry and Laboratory Medicine educational recommendations, macrotroponin presence was assessed in the top 10% cTn samples using immunoglobulin G (IgG) depletion screening and a reference sucrose gradient, confirming macrotroponin when both methods concurred. Due to analytical dilution constraints, [the highest] 88 of 135 Siemens Atellica high-sensitivity cTnI (hs-cTnI) samples were analyzed with both methods. All 106 Roche hs-cTnT samples were negative using IgG depletion, and sucrose analysis was limited to the highest 70 samples. Results Macrotroponin was found in 76% (67/88) of Siemens samples but in none of the Roche samples (0/70). Excluding macrotroponin-affected samples lowered the Siemens 99th percentiles from 117 ng/L to 22 ng/L in men and from 37 ng/L to 9 ng/L in women. The 99th/50th percentile ratio for Siemens decreased from 12- to 29-fold to 3- to 7-fold, approaching the Roche ratios. Conclusions Macrotroponin significantly influenced the Siemens Atellica hs-cTnI 99th percentiles, suggesting important clinical implications that warrant further prospective studies. The 99th/50th percentile ratio may help evaluate macrotroponin interference in troponin assays.
Artificial Intelligence in Gastroenterology Education: DeepSeek Passes the Gastroenterology Board Examination and Outperforms Legacy ChatGPT Models
Ibrahim, Andrew , Danpanichkul, Pojsakorn , Hayek, Alberto , Paul, Elahna , Farag, Annmarie , Mansoor, Masab , Cheungpasitporn, Wisit , Othman, Mohamed O. , Ibrahim, Andrew F , Hayek, Alexander , Paul, Edwin , Cheungpasitporn, Wisit , Othman, Mohamed O , Danpanichkul, Pojsakorn , Thongprayoon, Charat

Mayo Clinic

American Journal of Gastroenterology | May 20, 2025 | Volume: 121 | Issue: 4 | Pages: 1041-1043

10.14309/ajg.0000000000003552 | PMID 40392256 Get It

INTRODUCTION: DeepSeek was evaluated in gastroenterology board examination performance against legacy ChatGPT offline models, which previously showed failing performance. METHODS: The performances of the DeepSeek base R1 model and search-augmented R1 model were assessed using American College of Gastroenterology self-assessments (455 questions). RESULTS: DeepSeek exceeded the passing threshold. Search-augmented DeepSeek scored 81.5% across all questions, and the R1 base model scored 77.1%. Both search-augmented and offline DeepSeek models surpassed offline ChatGPT-3 (65.1%) and ChatGPT-4 (62.4%) ( P < 0.001). DISCUSSION: DeepSeek exhibited passing performance on the gastroenterology board examination but had gaps in niche topics and image exclusion limit utility. It may supplement education if validated by specialists.
0831 Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Results from the DUET Study
Schneider, Logan , Ruoff, Chad , Nichols, Deborah A. , Steininger, Teresa L. , Fuller, Douglas S. , Akerman, Sarah , Alexander, Jessica, Whalen, Marisa, Cairns, Alyssa , Ruoff, Chad M , Plante, David T. , Kirby, M

Mayo Clinic

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A360-A360

10.1093/sleep/zsaf090.0831 Get It

Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) assessing the effectiveness of low-sodium oxybate (LXB; Xywav®) treatment on daytime and nighttime symptoms in participants with narcolepsy (type 1 [NT1] or 2 [NT2]) or idiopathic hypersomnia. Data presented are from the narcolepsy cohort. Methods DUET included a screening period (with 2-week washout for current oxybate users), 8-day baseline (BL) period, 2- to 8-week LXB titration period, 2-week stable-dose period, 8-day end-of treatment (EOT) period, and 2-week safety follow-up. The primary endpoint was change in Epworth Sleepiness Scale (ESS) score from BL to EOT. Key secondary endpoints for the narcolepsy cohort included change in polysomnography parameters: total shifts from deeper to lighter sleep stages, stage N3 sleep duration (minutes), and number of awakenings. Additional endpoints included Patient Global Impression of Change (PGIc)–overall narcolepsy disease. Primary and key secondary endpoints were controlled for multiplicity with sequential testing; other P-values are considered nominal. Results Fifty-five narcolepsy participants enrolled and were dosed with LXB (NT1, n=26; NT2, n=29); 13 transferred to another cohort and 34 were completers (NT1, n=16; NT2, n=18). Enrolled participants were mostly female (72.7%) and White (80.0%); mean (SD) age was 33.4 (12.9) years (NT1=34.6 [12.6]; NT2=32.4 [13.2]). For completers, least-squares mean (LSM) (SE) changes in ESS score were −7.7 (0.9), P&lt;.0001, overall; NT1=−6.5 (1.4), P&lt;.0001; NT2=−8.8 (1.3), P&lt;.0001. Compared with BL, sleep architecture at EOT showed fewer deeper to lighter sleep stage shifts (LSM [SE]: −13.1 [2.9], P&lt;.0001, overall; NT1=−13.9 [4.3], P=0.0029; NT2=−12.3 [4.1], P=0.0050); increased stage N3 sleep (minutes) (45.0 [8.8], P&lt;.0001, overall; NT1=49.8 [13.0], P=0.0006; NT2=40.8 [12.3], P=0.0023); and fewer awakenings (−3.2 [0.9], P=0.0015, overall; NT1=−4.1 [1.4], P=0.0056; NT2=−2.3 [1.3], P=0.0771). Most participants (93.3%, n=30; NT1, 86.7%, n=15; NT2, 100%, n=15) reported improvement (very much, much, minimally) in overall narcolepsy disease on PGIc. Treatment-emergent adverse events were consistent with the known safety profile of LXB. Conclusion Participants with NT1 and NT2 taking open-label LXB showed improvements in daytime sleepiness (decreased ESS scores) and reduced symptom burden (improved PGIc), which paralleled improvements in sleep architecture and disruption. Support (if any) Jazz Pharmaceuticals
0851 Effectiveness and Safety of Low-Sodium Oxybate in Idiopathic Hypersomnia Participants: Results from the DUET Study
Cairns, Alyssa , Schneider, Logan , Nichols, Deborah A. , Steininger, Teresa L. , Kirby, Melanie, Akerman, Sarah , Alexander, Jessica, Whalen, Marisa, Ruoff, Chad , Ruoff, Chad M , Plante, David T. , Fuller, Douglas, Kirby, M

Mayo Clinic

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A369-A369

10.1093/sleep/zsaf090.0851 Get It

Abstract Introduction Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on daytime and nighttime symptoms, including excessive daytime sleepiness (EDS) and polysomnography in participants with idiopathic hypersomnia (IH) or narcolepsy. Data presented are from the IH cohort. Methods DUET included screening (with 2-week washout for oxybate users), 8-day baseline (BL), 2- to 8-week LXB titration, 2-week stable-dose, 8-day end-of-treatment (EOT), and 2-week safety follow-up periods. The primary endpoint was change in Epworth Sleepiness Scale (ESS) score from BL to EOT. Secondary endpoints for the IH cohort included change in Idiopathic Hypersomnia Severity Scale (IHSS) total score, Patient Global Impression of Change (PGIc)−overall IH disease, PGIc−sleep inertia, and Patient Global Impression of Severity (PGIs)−sleep inertia. Exploratory endpoints included IHSS component scores (daytime functioning, sleep inertia). Primary and key secondary (IHSS total score) endpoints were controlled for multiplicity with sequential testing; all other P-values are considered nominal. Results Forty-six people with IH enrolled and were dosed with LXB; 40 were completers. Enrolled participants were mostly female (80.4%) and White (84.8%), with a mean (SD) age of 38.1 (11.8) years. For completers, BL mean (SD) ESS score and IHSS total score were 16.5 (2.7) and 32.9 (7.1), respectively; least-squares mean (LSM) (SE) changes from BL to EOT were −8.4 (0.7), P&lt;.0001 and −15.5 (1.5), P&lt;.0001. BL mean (SD) IHSS component scores for daytime functioning and sleep inertia were 17.7 (4.2) and 10.7 (3.1), respectively; LSM (SE) changes from BL to EOT were −8.8 (1.0), P&lt;.0001 and −4.8 (0.4), P&lt;.0001. At EOT, most participants reported improvement (very much, much, minimally) on PGIc−overall IH disease (94.6%) and PGIc−sleep inertia (81.1%). At BL, 25.0% of participants reported sleep inertia severity as very mild/mild/not present on PGIs–sleep inertia vs 59.0% at EOT. Treatment-emergent adverse events were consistent with the known safety profile of LXB. Conclusion People with IH taking open-label LXB showed improvements in EDS and sleep inertia (decreased ESS and IHSS component scores) and reported reduced multi-symptom burden (decreased IHSS total scores and improved PGIc/PGIs ratings). Support (if any) Jazz Pharmaceuticals
0862 Sleep Architecture with Low-Sodium Oxybate Treatment in Narcolepsy: Results from the DUET Study
Ruoff, Chad , Schneider, Logan , Nichols, Deborah A. , Steininger, Teresa L. , Fuller, Douglas S. , Kirby, Matthew , Alexander, Jessica, Mignot, Emmanuel , Ruoff, Chad M , Sangal, R. Bart , Kirby, M

Mayo Clinic

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A374-A374

10.1093/sleep/zsaf090.0862 Get It

Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes including polysomnography (PSG)-based sleep architecture in participants with idiopathic hypersomnia or narcolepsy (type 1 [NT1] or 2 [NT2]). Methods DUET included a screening period (2-week washout for current oxybate users), 8-day baseline (BL) period, 2- to 8-week LXB titration period, 2-week stable-dose period (SDP), 8-day end-of-treatment period (EOT), and 2-week safety follow-up. Participants underwent nocturnal PSG (ad libitum protocol) at BL and EOT. PSGs were scheduled to allow a minimum of 10 hours in bed, unless the participant naturally awakened earlier; bedtime was determined by habitual bedtime. PSG recordings were centrally scored. Data were analyzed for participants in the narcolepsy cohort completer set. Total shifts from deeper to lighter sleep stages was defined as N1/N2/N3/REM to wake and N2/N3/REM to N1. Key secondary endpoints (total stage shifts, N3 duration) were controlled for multiplicity with sequential testing; other P-values are considered nominal. Results Fifty-five participants with narcolepsy enrolled (NT1, n=26; NT2, n=29); 34 completed the study (NT1, n=16; NT2, n=18). Most were female (73%) and White (80%) (mean±SD age, 33.4±12.9 years). Mean±SD total sleep time (TST) at BL/EOT was 453.2±80.1/452.4±70.0 minutes (LSM change [95% CI]: –0.78 [–23.7, 22.1]; P=.9451). Mean±SD number of total shifts from deeper to lighter sleep stages at BL/EOT was 54.6±28.0/41.6±25.6 (LSM [95% CI]: –13.1 [–19.0, –7.1]; P&lt;.0001 [controlled for multiplicity]). Mean±SD time spent in N1 at BL/EOT was 45.3±28.4/37.2±25.2 minutes (LSM [95% CI]: –8.1 [–14.9, –1.4]; P=.0196), % of stage was 10.4%/8.2% (P=.0037); in N2 was 241.8±61.2/243.3±76.1 minutes (LSM [95% CI]: 1.5 [–23.6, 26.6]; P=.9040), 53.1%/53.2% (P=.9869); in N3 was 61.1±34.8/106.1±69.5 minutes (LSM [95% CI]: 45.0 [27.0, 63.0]; P&lt;.0001 [controlled for multiplicity]), 13.7%/24.0% (P&lt;.0001); and in REM was 105.0±42.7/65.8±33.1 minutes (LSM [95% CI]: –39.2 [–50.8, –27.5]; P&lt;.0001), 22.8%/14.7% (P&lt;.0001). Conclusion Participants with narcolepsy taking open-label LXB showed negligible change in TST and N2, increased N3, decreased N1 and REM, and fewer shifts from deeper to lighter stages of sleep. Support (if any) Jazz Pharmaceuticals
Clinical risk factors for body composition deficits in children with inflammatory bowel disease
Alexander, Erin , Stein, Ronen , Rudra, Sharmistha , Albenberg, Lindsey , Zemel, Babette S.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | May 19, 2025 | Volume: 81 | Issue: 2 | Pages: 266-274

10.1002/jpn3.70075 | PMID 40384504 Get It

AbstractObjectivesChildren with inflammatory bowel disease (IBD) often have low body mass index (BMI). BMI does not distinguish between fat and lean mass. Body composition deficits may be associated with worse clinical outcomes. We examined the prevalence of risk factors associated with body composition deficits in youth with pediatric‐onset IBD, and factors associated with low lean mass in the presence of a normal BMI Z‐score (BMI‐Z).MethodsNewly diagnosed IBD patients ages 5–20 years with whole body dual energy x‐ray absorptiometry scans acquired between 2014 and 2019 were included. Appendicular lean soft tissue mass index (AppLSTMI) and fat mass index (FMI) were expressed as age and sex‐specific Z‐scores. Clinical and demographic data were collected retrospectively. Logistic regression was used to assess associations with body composition outcomes.ResultsFive hundred sixteen patients were included, 26% had AppLSTMI Z‐score (AppLSTMI‐Z) < −2, 4% had BMI‐Z < −2, and none had FMI Z‐score (FMI‐Z) < −2. Increased risk of low AppLSTMI‐Z associated with Crohn's diagnosis, Asian ethnicity, disease activity, elevated platelets, and glucocorticoid use. Females had lower FMI‐Z. Low AppLSTMI‐Z within the context of BMI‐Z (n = 112) was associated with Crohn's disease, Asian (odds ratio [OR] = 3.77, p = 0.001) and Black identity (OR = 0.32, p = 0.02), and elevated platelets (OR = 1.76, p = 0.02) compared to those with normal BMI‐Z and normal AppLSTMI‐Z.ConclusionsBMI is a poor indicator of body composition in children with IBD as it masks lean mass deficits which are highly prevalent. Future studies regarding the long‐term consequences and reversibility of this deficit are warranted.
Guidelines Against Discrimination and Bias in Anatomical Research Papers (GDBARP): Recommendations From Anatomical Journal Editors
Takeda, Sén, Sol, Mariano del , Ravi, Kumar Satish , Singh, Vishram, Apaydın, Nihal, Kim, Hee‐Jin , Adds, Philip J. , Loukas, Marios , Tubbs, R. Shane, Del Sol, Mariano , Ravi, Kumar Satish , Apaydin, Nihal , Adds, Philip , Loukas, Marios , Iwanaga, Joe , Walocha, Jerzy Andrzej , Ribatti, Doménico , Moryś, Janusz , Paulsen, Friedrich P. , Duparc, Fabrice

Mayo Clinic

Clinical Anatomy | May 19, 2025 | Volume: 38 | Issue: 5 | Pages: 613-618

10.1002/ca.24293 | PMID 40384060 Get It

ABSTRACTMost discussions about discrimination and bias in anatomical research papers have been limited to terminology relating to race/ethnicity and gender/sex. However, as editors of anatomical journals, the authors of this article have frequently observed broader instances of potential discrimination and bias within anatomical research. These often stem from differences among authors' backgrounds, traditions, cultures, religions, provenance/origins, and workplace affiliations. In view of the limited discourse on this topic, we seek in this article to establish a consensus among editors of anatomical journals and to propose new Guidelines Against Discrimination and Bias in Anatomical Research Papers (GDBARP). We have identified multiple factors that can contribute to discrimination and bias, underscoring the need for greater awareness and proactive measures. It is imperative in anatomical research to respect authors, reviewers, and editors regardless of their background, culture, traditions, sex, ethnicity, language, religion, or ethical perspectives.
The International Classification of Vestibular Disorders: Achievements, challenges, and future directions
Kaski, Diego , Tarnutzer, Alexander A. , Carey, John P. , Cha, Yoon‐Hee , Eggers, Scott D.Z. , Furman, Joseph M. , Kim, Hyun Ah , Lempert, Thomas , López‐Escámez, José A. , Magnusson, Måns , Newman‐Toker, David E. , Seemungal, Barry M. , Berg, Raymond van de , Brevern, Michael von , Bisdorff, Alexandre , Cha, Y H , Eggers, Scott Dz, Lempert, Thomas , López-Escámez, Jose A , Magnusson, Mans , Newman-Toker, David E , Seemungal, Barry M , Staab, Jeffrey P , Agrawal, Yuri , Kim, Ji‐Soo , Staab, Jeffrey P. , Strupp, Michael Leo , Ward, Bryan Kevin

Mayo Clinic

Journal of Vestibular Research | May 17, 2025 | Volume: 35 | Issue: 3 | Pages: 105-112

10.1177/09574271251313803 | PMID 39973600 Get It

In 2007, the Bárány Society embarked on a project to establish definitions of vestibular syndromes and disorders based on best available evidence, referred to as the International Classification of Vestibular Disorders (ICVD). Since then, numerous publications providing consensus-driven diagnostic criteria for vestibular symptoms, syndromes, and disorders have been published. Here, we reflect on the rationale for developing the ICVD as well as its subsequent achievements, challenges, and outlook. In this summary of the work of the ICVD to date, the authors will focus on practical aspects to help improve the utility and applicability of these diagnostic criteria moving forward.
Outcomes of Multiply Revised ACL Reconstruction with Quadriceps Tendon Autograft plus Lateral Extra-articular Tenodesis in Competitive Athletes
Tummala, Sailesh V. , Brinkman, Joseph C. , Parmar, Romir , Haglin, Jack M. , Hoffer, Alexander J , Economopoulos, Kostas J. , Tummala, Sailesh V

Mayo Clinic

Orthopaedic Journal of Sports Medicine | May 16, 2025 | Volume: 13 | Issue: 5 | Pages: No page available

10.1177/23259671251337478 | PMID 40386643 Get It

Background: The number of multiply revised anterior cruciate ligament reconstructions (rrACLRs) performed each year continues to increase. The most reliable graft type and surgical technique in the young, active patient remains to be determined. Purpose: To determine the outcomes of rrACLR using quadriceps tendon (QT) autograft with lateral extra-articular tenodesis (LET). Study Design: Case series; Level of evidence, 4. Methods: A retrospective review was performed of all competitive athletes undergoing rrACLR with QT autograft and LET at a single institution with a minimum follow-up of 2 years. Patient demographics, physical examination, and radiological findings, and previous surgical details were documented. Patient outcomes were noted, including the International Knee Documentation Committee (IKDC) and Lysholm scores, ability to return to sport and return at the same level of play, retear rate, and other complications. Results: A total of 19 rrACLRs were performed and met inclusion criteria in the 10-year study period. All participants were high school, collegiate, or professional athletes with a mean age of 22 years, and 63.2% were female. The mean follow-up was 42.3 months, and IKDC scores increased from 51.6 preoperatively to 74.7 at the final follow-up ( P < .001). Likewise, the Lysholm score increased significantly from a preoperative value of 53.6 to 76.8 at the final follow-up ( P < .001). Return to play was possible in 52.6% of the patients at a mean of 11.5 months, with 31.6% returning to the same or higher level of play. One (5.3%) patient experienced a recurrent ACL tear, and 2 (10.5%) experienced a contralateral tear. Arthrofibrosis requiring surgical intervention occurred in 26.3% of the athletes. Conclusion: Short- to midterm results demonstrated that competitive athletes who received an rrACLR using a QT autograft with LET had statistically significant improvements in both IKDC and Lysholm scores, with more than half of patients being able to return to sport and nearly a third returning at the same or higher level of play. In the setting of a third ACL reconstruction, quadriceps tendon autograft with LET is a reasonable option even in high-risk patients.